How to read an FDA Form 483 for a compounding pharmacy

01

What a Form 483 means

FDA says investigators issue Form 483 to firm management at the conclusion of an inspection when observed conditions may constitute violations of the federal law and related requirements. The observations are intended to be clear, specific, and significant, and management can discuss them with investigators at the close of the inspection.

The form is not a comprehensive audit report, a product approval, or a final agency determination. It reflects observations from a defined inspection period. A facility may respond with a corrective-action plan, and FDA may evaluate the response and other evidence before deciding whether to take further action.

02

Match the exact facility before reading

Compounding organizations may operate under multiple legal names, trade names, addresses, or related companies. Search FDA's compounding inspections page by the legal entity and doing-business-as name, then confirm the street address and whether the entry is described as a 503A pharmacy or 503B outsourcing facility. Do not assign one location's record to another facility merely because the brands are related.

Record the inspection dates, issue date, page count, and whether the document is a 483, warning letter, untitled letter, state referral, recall notice, response, regulatory-meeting note, or closeout. These documents represent different stages and should not be collapsed into the word citation.

03

Read observations without overclaiming

Review each observation and identify the process involved, such as sterile practices, environmental monitoring, cleaning, testing, investigations, labeling, or complaint handling. Note whether the observation describes a single example, repeated examples, a missing procedure, inadequate documentation, or an observed practice. Avoid translating technical language into a diagnosis about a specific patient's product.

A 483 can reveal questions worth asking, but it usually cannot tell a consumer whether a particular vial was affected or whether the firm corrected the issue. Do not turn an observation into a claim of contamination, patient harm, fraud, or current noncompliance unless a later authoritative record supports that conclusion.

04

Follow the chronology after the 483

Look for a publicly posted firm response and note what evidence the firm says it provided. A response is the firm's account, not an independent FDA confirmation. Then search for a warning letter, which communicates FDA's position on significant violations, and for a closeout letter or later inspection that may show subsequent agency activity.

Also check recalls and state-board actions. FDA sometimes refers matters involving state-licensed pharmacies to a state regulator, and states oversee pharmacy licensure and practice. The absence of a later public document does not prove that every observation was corrected; public files may be incomplete or updated on different schedules.

• →Form 483: inspectional observations
• →Firm response: the company's corrective-action account
• →Warning letter: agency notice of significant violations
• →Closeout letter: FDA's evaluation of corrective actions for the cited issues
• →Recall or state action: a separate event requiring its own scope and date

05

Special limits of a 503B registration claim

FDA states that 503B registration means the agency received the required registration information. It does not mean FDA approved the facility's compounded drugs or determined the facility complies with current good manufacturing practice and every condition of section 503B.

FDA also cautions that an inspection is a snapshot in time. A recent satisfactory inspection can provide some assurance about conditions at that time, but conditions can change. Consumers should verify the specific facility, current registration period, inspection history, recalls, and the exact product source.

06

Turn the record into fair provider questions

Ask the clinic or pharmacy which physical facility compounded the product, whether that address matches the label, what changed after the inspection, whether affected lots were recalled, and where the most recent regulator record can be found. Request direct records rather than a statement such as FDA inspected or 503B certified.

Use neutral language in your notes: FDA observed, the firm responded, FDA issued, or the board reported. Date every statement. A responsible provider should be able to identify the dispensing pharmacy and discuss how complaints, recalls, storage, and follow-up are handled without portraying a regulatory category as a safety guarantee.

07

Build a dated inspection evidence table

A simple evidence table prevents an old observation from being presented as a current condition. Use one row per document with the facility name and address, document type, inspection or issue date, regulator, observation or action, firm's stated response, later follow-up, and direct URL. Keep fact, firm statement, and your inference in separate columns.

For each observation, write the narrowest supported summary. For example, say that an investigator documented a named practice during a specified inspection, not that the pharmacy always follows that practice. If a warning letter later cites the same issue, link the records; if a closeout addresses it, note exactly which letter was closed and when.

Recheck the table immediately before publication or a purchasing decision. FDA and state pages can add later documents, facilities can change names or registration status, and recalls can be classified after posting. A transparent chronology is more useful than a permanent good-or-bad label.

• →Separate observation date from document-posting date.
• →Quote sparingly and preserve the regulator's terminology.
• →Label firm responses as firm-provided claims.
• →Record missing follow-up as not located, not as proof of no action.